title: Technology evaluation: NV-1020, MediGene.
abstract: NV-1020 is a recombinant oncolytic HSV-based virus, in development by MediGene (formerly NeuroVir) for the potential treatment of cancer. The therapy is currently undergoing phase II clinical trials.
authors.affiliation: Academy of Sciences of the Czech Republic, Institute of Molecular Genetics, Flemingovo nam 2, Prague 6, CZ-16637. reinis@img.cas.cz
authors.forename: Milan
authors.initials: M
authors.lastname: Reinis
mesh_terms: D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D005818:Genetic Engineering; D015316:Genetic Therapy / Q000009:adverse effects / Q000379:methods*; D018259:Herpesvirus 1, Human / Q000235:genetics*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D009369:Neoplasms / Q000628:therapy*